Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Portfolio Pulse from Vandana Singh
Alzheimer's drug Leqembi, developed by Eisai Co Ltd and Biogen Inc, faces hurdles in Europe due to concerns over health risks and healthcare resources. The drug is undergoing regulatory review in Europe and is likely to receive approval in the U.S. next month. However, European countries prioritize cost-effectiveness, and analysts predict a smaller European market for the drug.
June 13, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biogen's Alzheimer's drug Leqembi faces hurdles in Europe due to health risks and healthcare resources, potentially limiting its market size.
The concerns over health risks and healthcare resources in Europe may limit the market size for Biogen's Alzheimer's drug Leqembi. European countries prioritize cost-effectiveness, and analysts predict a smaller European market for the drug, which could negatively impact Biogen's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Eisai's Alzheimer's drug Leqembi, developed in partnership with Biogen, faces hurdles in Europe due to health risks and healthcare resources, potentially limiting its market size.
The concerns over health risks and healthcare resources in Europe may limit the market size for Eisai's Alzheimer's drug Leqembi, developed in partnership with Biogen. European countries prioritize cost-effectiveness, and analysts predict a smaller European market for the drug, which could negatively impact Eisai's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100